- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
De novo aggregation of Alzheimer’s Aβ25-35 peptides in a lipid bilayer ; volume:9 ; number:1 ; day:9 ; month:5 ; year:2019 ; pages:1-12 ; date:12.2019
Scientific reports ; 9, Heft 1 (9.5.2019), 1-12, 12.2019
- Classification
-
Biowissenschaften, Biologie
- Creator
-
Smith, Amy K.
Klimov, Dmitri K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-43685-7
- URN
-
urn:nbn:de:101:1-2019053022295218322864
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Smith, Amy K.
- Klimov, Dmitri K.
- SpringerLink (Online service)
Other Objects (12)
C3N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
The plasma peptides of Alzheimer’s disease
Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
The role of N-truncated Aβ peptides in Alzheimer’s Disease
SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease
Optimization and characterization of D-peptides for treatment of Alzheimer’s disease
C3N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
The plasma peptides of Alzheimer’s disease
Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
The role of N-truncated Aβ peptides in Alzheimer’s Disease
SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease
Optimization and characterization of D-peptides for treatment of Alzheimer’s disease
C3N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
The plasma peptides of Alzheimer’s disease
Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
The role of N-truncated Aβ peptides in Alzheimer’s Disease
SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Monitoring Alzheimer Amyloid Peptide Aggregation by EPR
Pharmacokinetic properties of D-peptides designed for treatment of Alzheimer’s disease